Register now for a full-day continuing medical education program delivering timely, clinically actionable updates across the lung cancer care continuum. Hosted by Fox Chase Cancer Center in collaboration with Penn Medicine’s Abramson Cancer Center, this dynamic multidisciplinary symposium features expert faculty from leading Philadelphia-area institutions — including speakers from both Fox Chase and Penn — along with Jefferson Health, Cooper Norcross Health, Alliance Cancer Specialists, and national experts from Memorial Sloan Kettering Cancer Center and The Ohio State University. Participants will gain a focused, high-impact review of evolving standards in early-stage disease, small cell lung cancer, targeted therapies, and emerging strategies shaping practice in 2026 and beyond.

Focused presentations, surgical and radiation perspectives, and interactive case-based discussions will provide practical insight into perioperative strategies, biomarker-driven treatment selection, emerging therapeutics, and real-world multidisciplinary decision-making. Attendees will leave with clear, actionable updates to apply in clinical practice.

DATE:
Saturday, October 17, 2026

TIMES:
7:30 AM – 8:00 AM Check-in & Breakfast
8:00 AM – 4:00 PM Education Program

LOCATION:
Philadelphia Marriott Old City
One Dock Street
Philadelphia, PA 19106

PROGRAM DIRECTORS:

 

KEYNOTE SPEAKERS:

 

 

TOPICS

• Recent Advances in Lung Cancer Treatment
• Biomarker-Driven Care
• HER2 Testing and HER2-Directed Therapies
• Targeted Therapies
• Bispecific Antibodies in Lung Cancer Care
• Early-Stage Disease
• Perioperative Strategies
• Small Cell Lung Cancer
• Emerging Therapeutics

LEARNING OBJECTIVES
By the end of this program, learners will be able to:

• Provide an update on the most recent changes in the treatment of lung cancer
• Explain the rationale and need for HER2 testing and HER2-directed treatment
• Describe the use of bispecific antibodies in lung cancer treatment 

AUDIENCE

• Physicians and Trainees
• Nurses
• Advanced Practice Providers
• Rehabilitation Specialists and Genetic Counselors
• Pharmacy, Radiology, and Pathology Professionals
• Patient Navigators and Other Healthcare Professionals Involved in Lung Cancer Care

WHAT YOU’LL GAIN FROM ATTEDNING

• Updates on the latest advances in lung cancer treatment and evolving standards of care
• Practical strategies for perioperative management and biomarker-driven treatment selection
• Multidisciplinary perspectives on real-world challenges and collaborative decision-making
• Tools and best practices you can apply immediately in clinical practice

ACCREDITATION STATEMENT:
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. Fox Chase Cancer Center is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

DESIGNATION STATEMENT:
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

Fox Chase Cancer Center designates this live activity for a maximum of 6 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABS MOC Statement: Successful completion of this CME activity enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

INQUIRIES:

Lucía Tono, Ph.D., M.Ed